Sintilimab in Combination With Chidamide in Refractory and Relapsed AITL

NCT04831710 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

83

Enrollment

OTHER

Sponsor class

Conditions

Angioimmunoblastic T-cell Lymphoma

Interventions

DRUG: Sintilimab
DRUG: Chidamide

Sponsor

Sun Yat-sen University